Excitotoxicity Research Dashboard
Double-blind human trials
Clinical human trials
What am I missing as a non-subscriber?
To see a full dashboard with study details and filtering, go to our DEMO page.
As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.
CannaKeys has 10 studies associated with Excitotoxicity.
Here is a small sampling of Excitotoxicity studies by title:
- The endocannabinoid system as a target for the treatment of neuronal damage
- URB597 Prevents the Short-Term Excitotoxic Cell Damage in Rat Cortical Slices: Role of Cannabinoid 1 Receptors
- Modulatory effect of 2-arachidonoylglycerol on voltage-gated sodium currents in rat caudate nucleus neurons with kainic acid-induced injury
- A Cannabinoid Receptor-Mediated Mechanism Participates in the Neuroprotective Effects of Oleamide Against Excitotoxic Damage in Rat Brain Synaptosomes and Cortical Slices
- A Pulsed Electromagnetic Field Protects against Glutamate-Induced Excitotoxicity by Modulating the Endocannabinoid System in HT22 Cells
Components of the Excitotoxicity Research Dashboard
- Dosing information available for Excitotoxicity
- Chemotype guidance for treating Excitotoxicity with cannabis
- Synopsis of cannabis research for Excitotoxicity
- Individual study details for Excitotoxicity
Ready to become a subscriber? Go to our PRICING page.
Members can filter by the following criteria:
- Study Type
- Cannabinoids & Endocannabinoids
- Study Result
- Year of Publication
Overview - Excitotoxicity
Description of Excitotoxicity
Excitotoxicity is a process by which nerve cells are negatively affected (to the point of destruction) by an over-abundance of stimulation most importantly the neurotransmitter glutamate. Underlying conditions contributing to excitotoxicity may include neurological conditions (e.g. ALS, Parkinson's), cerebro-vascular accidents (stroke), or traumatic damages to the brain and/or spinal cord, as well as severe physical withdrawal from drugs (e.g. alcohol).
Toxic Exposure (Glutamate)
Symptoms, Signs and Abnormal Clinical and Laboratory Findings
ICD-10 Code: R29.8
Hyperactivation of glutamate receptor
Also known as:
Tetany, Meningismus, Clicking Hip
THC Interaction with Pharmaceutical Drugs
- THC can enhance the effects of drugs that cause sedation and depress the central nervous system, such as benzodiazepines, barbiturates, and alcohol, for example.
- THC is metabolized by and an inhibitor of a number of enzymatic liver pathways referred to as cytochrome P450. There are more than 50 enzymes belonging to this enzyme family, a number of which are responsible for the breakdown of common drugs such as antidepressants (e.g. amitriptyline, doxepine, fluvoxamine), antipsychotics (haloperidol, clozapine, stelazine), beta-blockers (e.g. propranolol), bronchodilators (e.g. theophylline), or bloodthinners (e.g. warfarin). Thus patients taking these classes of medication may find that THC increases the concentration and effects of these drugs as well as the duration of their effects.
- Clinical observation suggests no likely interactions with other pharmaceuticals at a total daily dose of up to 20mg THC.
CBD Interaction with Pharmaceutical Drugs
- CBD may alter action on metabolic enzymes (certain drug-transport mechanisms), and as such may alter interactions with other drugs, some of which may produce therapeutic or adverse effects. For instance, CBD interacts with the enzyme cytochrome P450 3A4 and cytochrome P450 2C19, increasing the bioavailability of anti-epileptic drugs such as clobazam (a benzodiazepine). This makes it possible to achieve the same results at significantly lower dosages, reducing treatment costs and risks of adverse effects.
- Groups of drugs affected include: anti-epileptic drugs, psychiatric drugs, and drugs affecting metabolic enzymes, for example.
- Clinical observations suggest no likely interactions with other pharmaceuticals at a total daily dose of up to 100mg CBD
THC Dosage Considerations
- THC micro dose: 0.1 mg to 0.4 mg
- THC low dose: 0.5 mg to 5 mg
- THC medium dose: 6 mg to 20 mg
- THC high dose: 21 mg to 50+ mg
CBD Dosage Considerations
- CBD low dose: 0.4 mg to 19 mg
- CBD medium dose: 20 mg to 99 mg
- CBD high dose: 100 mg to 800+ mg (upper limits tested ~1,500mg)
Disclaimers: Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for diagnosing a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider.
Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.